Positive hepatitis B E antibody is generally a sign of reduced hepatitis B virus (HBV) replication and diminished infectiousness, and is used for infectiousness evaluation and also for judgment of HBV variant strain infection. Hepatitis B E antibody mostly appears about 1 month after the hepatitis B E antigen subsides, but if there is an abnormal transaminase, HBV variant strain infection should be suspected to be infectious: 1. The condition is improving: hepatitis B E antigen negative, hepatitis B E antibody positive for inactive carriers, hepatitis B E antigen converted to hepatitis B E antibody, antibody content is closely related to viral replication, high antibody content suggests little or no viral replication, may In hepatitis recovery or prove that the treatment is effective; 2. Hepatitis B chronicity: as hepatitis B chronicity increases, the detection rate of hepatitis B E antigen positivity decreases, while the detection rate of hepatitis B E antibody positivity has a tendency to increase. In cirrhosis and liver cancer, the detection rate of hepatitis B E antibody positivity is higher than that of hepatitis B E antigen positivity, suggesting that hepatitis B E antibody positivity is prone to chronicity and severe development of hepatitis, and also prone to cirrhosis and liver cancer; 3. Variant strain infection: it is an atypical manifestation of hepatitis, although the patient shows hepatitis B E antibody positivity, but HBV continues to replicate in the body. In summary, positive hepatitis B E antibody does not completely indicate that the virus replication is reduced and infectious is weak, HBV may still continue to replicate in the body, it should be combined with hepatitis B E antigen and other antigens, antibodies and clinical manifestations of patients and other comprehensive judgment. For those with abnormal liver function, drugs such as reduced glutathione and glycopyrrolate preparations can be used appropriately, and antiviral drugs can also be used as appropriate to control disease progression.